Bowel cancer diagnosis typically begins with a simple stool test and, if results are positive, moves to a colonoscopy where tissue samples can be taken and examined under a microscope. Most people at average risk should start screening at age 45, and the process from first test to a confirmed diagnosis usually involves several steps, each narrowing down whether cancer is present, where it is, and how far it may have spread.
Stool Tests: The First Step
The most common starting point is a fecal immunochemical test, or FIT. This is a simple at-home kit that detects tiny amounts of blood in your stool, which can be invisible to the naked eye. A positive result triggers a return of 40 or more micrograms of hemoglobin per gram of stool. In clinical use, the FIT has a sensitivity of about 96% for detecting bowel cancer, meaning it catches the vast majority of cancers. Its negative predictive value is 99.8%, so a negative result is very reassuring. A positive FIT does not mean you have cancer. It means blood was found, and further investigation is needed. Hemorrhoids, inflammation, and other non-cancerous conditions can also cause a positive result.
Colonoscopy: The Gold Standard
If your stool test comes back positive, the next step is almost always a colonoscopy. During this procedure, a thin, flexible tube with a camera is guided through your entire large bowel. The doctor can see the lining in real time and, critically, can take tissue samples (biopsies) or remove polyps on the spot. Quality benchmarks require that doctors find precancerous growths, called adenomas, in at least 25% of screening colonoscopies across a mixed-gender population. Higher detection rates are linked to significantly better protection against bowel cancer developing in the following five years.
Preparation involves clearing your bowel the day before with a strong laxative drink. The procedure itself typically takes 20 to 40 minutes, and you’ll receive sedation so you’re comfortable throughout. Afterward, you should be able to resume normal activities within 24 hours. If polyps were removed or biopsies taken, a small amount of bleeding from your bowel the next time you use the toilet is normal and usually settles within a day. Some bloating or abdominal discomfort from the air used to inflate the bowel during the exam is also common and resolves quickly.
CT Colonography as an Alternative
When a full colonoscopy isn’t possible or appropriate, CT colonography (sometimes called a virtual colonoscopy) uses a CT scanner to create detailed images of the bowel. For polyps 10 mm or larger, its detection rate is broadly comparable to a standard colonoscopy, with most studies reporting sensitivity between 75% and 92%. For smaller polyps in the 6 to 9 mm range, accuracy drops considerably, with studies showing detection rates as low as 12% and rarely above 60%. And for polyps under 5 mm, performance is poor. The key limitation: if something suspicious is found on a CT colonography, you’ll still need a standard colonoscopy to biopsy or remove it.
Blood Tests and Their Limits
A blood marker called CEA (carcinoembryonic antigen) is sometimes mentioned in the context of bowel cancer, but it is not used to screen for or diagnose cancer. Healthy adults have little or no CEA in their blood, and elevated levels can occur with other conditions. CEA’s real value comes after a diagnosis has been made. It helps doctors gauge how likely cancer is to respond to treatment, monitor whether treatment is working, and detect if cancer returns after treatment. If your doctor orders a CEA test, it will typically be alongside other investigations rather than as a standalone diagnostic tool.
A newer option is the Shield blood test, the first blood-based screening test approved by the FDA for average-risk adults. It works by detecting specific DNA changes in the bloodstream that signal the presence of a tumor or precancerous growth. In a study of nearly 8,000 people, Shield detected colorectal cancers with 83% sensitivity and had a specificity of 90%. However, it caught only about 13% of advanced precancerous polyps. This makes it a reasonable option for people who are unwilling or unable to do a stool test or colonoscopy, but it’s not a replacement for colonoscopy when it comes to finding and removing growths before they become cancer.
Biopsy and Pathology
A definitive bowel cancer diagnosis comes from examining tissue under a microscope. During a colonoscopy, the doctor removes suspicious tissue or entire polyps and sends them to a pathology lab. Pathologists determine whether the cells are cancerous, what type of cancer it is, and how abnormal the cells look (the grade). This process usually takes a few days to a couple of weeks.
For cancers that have spread or are advanced, the biopsy tissue undergoes molecular testing to look for specific genetic changes that influence treatment options. The most important markers include mutations in genes called KRAS, NRAS, and BRAF, along with a feature called microsatellite instability (MSI). About 9% of metastatic bowel cancers carry a specific BRAF mutation that predicts resistance to certain targeted therapies. MSI testing is particularly important because tumors with this feature respond well to a class of drugs called immune checkpoint inhibitors. These molecular results help oncologists match treatment to the biology of your specific cancer.
Staging: How Far the Cancer Has Spread
Once bowel cancer is confirmed, staging determines how advanced it is. This guides treatment decisions more than almost any other factor. Staging relies on imaging scans, usually CT scans of the chest, abdomen, and pelvis, sometimes supplemented with MRI for rectal cancers. Doctors use the TNM system, which evaluates three things: the tumor itself, nearby lymph nodes, and whether cancer has spread to distant organs.
The tumor (T) score describes how deeply cancer has grown into the bowel wall. At its earliest (T1), it’s confined to the inner lining. T2 means it has reached the muscle layer. T3 means it has pushed through the muscle into surrounding tissue but hasn’t breached the outer surface. T4 means it has either broken through the outer lining of the bowel or grown directly into a nearby organ.
The node (N) score reflects whether cancer cells have reached nearby lymph nodes. N0 means none are affected. N1 means one to three nodes contain cancer. N2 means four or more nodes are involved.
The metastasis (M) score captures distant spread. M0 means no spread. M1a means cancer has reached one distant organ, most commonly the liver. M1b means two or more distant sites are involved. M1c means cancer has spread to the peritoneum, the tissue lining the abdominal cavity, which carries a different prognosis.
These three scores combine into an overall stage, from stage I (small, localized) through stage IV (spread to distant organs). Your medical team will walk you through your specific staging results and what they mean for your treatment plan.
Recommended Screening Timeline
The U.S. Preventive Services Task Force recommends that adults between 45 and 75 be screened for colorectal cancer. If you’re at average risk, screening should begin soon after turning 45. People with a family history of bowel cancer or certain inherited conditions may need to start earlier. The type of screening and how often you need it depends on which test is used: stool-based tests are typically repeated every one to two years, while a colonoscopy with normal results may not need repeating for ten years.